Efficacy and comparative effectiveness of sirolimus as an anticancer drug

Laryngoscope

Volumn 121, Issue 5, 2011, Pages 978-982

  Hu, Melissa ^a,b   Ekshyyan, Oleksandr ^a,b   Ferdinandez, Lilantha Herman ^a   Rong, Xiaohua ^a,b   Caldito, Gloria ^b   Nathan, Cherie Ann O ^a,b  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

head and neck squamous cell carcinoma; Sirolimus; temsirolimus

Indexed keywords

RAPAMYCIN; TEMSIROLIMUS;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IN VIVO STUDY; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURGICAL WOUND; TREATMENT DURATION; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; HEAD AND NECK NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; SIROLIMUS;

EID: 79955548256     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.21724     Document Type: Article

References (27)

1. Sehgal SN, Baker H, Vezina C,. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975; 28: 727-732.
2. Huang S, Houghton PJ,. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 2002; 3: 295-304. (Pubitemid 34456089)
3. Shaw RJ, Cantley LC,. Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature 2006; 441: 424-430. (Pubitemid 44050136)
4. Vivanco I, Sawyers CL,. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501. (Pubitemid 37328931)
5. Amornphimoltham P, Patel V, Sodhi A, et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 2005; 65: 9953-9961. (Pubitemid 41541476)
6. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM,. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 1998; 95: 1432-1437. (Pubitemid 28103409)
7. Chan S,. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004; 91: 1420-1424. (Pubitemid 39486341)
8. Stepkowski SM, Tian L, Wang ME, Qu X, Napoli K, Kahan BD,. Sirolimus in transplantation. Arch Immunol Ther Exp (Warsz) 1997; 45: 383-390. (Pubitemid 28098863)
9. Abizaid A,. Sirolimus-eluting coronary stents: a review. Vasc Health Risk Manag 2007; 3: 191-201. (Pubitemid 46860708)
10. Kolhe N, Mamode N, Van der Walt J, Pattison J,. Regression of post-transplant Kaposi's sarcoma. Int J Clin Pract 2006; 60: 1509-1512.
11. Krischock L, Beach R, Taylor J,. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas. Arch Dis Child 2010; 95: 391-392.
12. Perl AE, Kasner MT, Tsai DE, et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 2009; 15: 6732-6739.
13. Ghiringhelli F, Guiu B, Chauffert B, Ladoire S,. Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study. World J Gastroenterol 2009; 15: 4278-4283.
14. Salgo R, Gossmann J, Schofer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010; 10: 1385-1393.
15. Schnitzbauer AA, Zuelke C, Graeb C, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10: 190.
16. Easton JB, Houghton PJ,. mTOR and cancer therapy. Oncogene 2006; 25: 6436-1646.
17. Pal SK, Figlin RA,. Treatment options in metastatic renal cell carcinoma: Focus on mTOR inhibitors. Clin Med Insights Oncol 2010; 4: 43-53.
18. Nathan CO, Amirghahari N, Rong X, et al. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 2007; 67: 2160-2168. (Pubitemid 46424235)
19. Ekshyyan O, Rong Y, Rong X, et al. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 2009; 8: 2255-2265.
20. Boni JP, Leister C, Bender G, et al. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 2005; 77: 76-89. (Pubitemid 40075391)
21. Nathan CA, Amirghahari N, Abreo F, et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2004; 10: 5820-5827. (Pubitemid 39180961)
22. Forastiere A, Koch W, Trotti A, Sidransky D,. Head and neck cancer. N Engl J Med 2001; 345: 1890-1900. (Pubitemid 33716564)
23. Shinohara ET, Maity A, Jha N, Lustig RA,. Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck. Head Neck 2009; 31: 406-411.
24. Hoffman JM, Doloresco F, Vermeulen LC, et al. Projecting future drug expenditures 2010. Am J Health Syst Pharm 2010; 67: 919-928.
25. Guba M, Koehl GE, Neppl E, et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 2005; 18: 89-94. (Pubitemid 41742951)
26. Clark C, Shah S, Herman-Ferdinandez L, et al. Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients. Laryngoscope 2010; 120: 1159-1165.
27. Abraham RT, Gibbons JJ,. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007; 13: 3109-3114. (Pubitemid 46944891)